Beyond Air, Inc. (NASDAQ: XAIR) Quarterly Earnings and Financial Health Overview

Beyond Air, Inc. (NASDAQ:XAIR) is a prominent player in the medical devices and biopharmaceuticals sector, known for its innovative healthcare products. The company is gearing up for its quarterly earnings release on June 17, 2025, with Wall Street analysts projecting an earnings per share (EPS) of -$0.14 and anticipated revenue of approximately $1.39 million.

XAIR has recently made headlines with its submission of a premarket approval (PMA) supplement application to the FDA for LungFit PH II, a next-generation therapeutic nitric oxide generator. This move is aimed at broadening its footprint in the nitric oxide market, a development eagerly watched by industry observers. A closer look at the company's financial metrics reveals a price-to-sales ratio of approximately 4.98, suggesting that investors are currently willing to pay nearly five times the company's sales per share. The enterprise value to sales ratio stands at about 4.12, offering a similar valuation perspective that takes into account the company's total value.

Notably, XAIR boasts a relatively low debt-to-equity ratio of 0.11, indicating a conservative approach to leveraging debt in its capital structure. This implies a preference for equity financing over debt. Furthermore, the company's strong current ratio of 3.56 underscores its robust liquidity position, with current assets more than tripling its current liabilities.

However, the company's financial health is not without its challenges. The negative price-to-earnings ratio and earnings yield highlight that XAIR is currently not profitable, raising concerns about its ability to generate sufficient profit relative to its share price. This aspect could potentially deter potential investors looking for immediate returns. In summary, Beyond Air, Inc. presents a mixed financial picture as it approaches its upcoming quarterly earnings announcement.